Revenue: As of FY2026, the actual value is USD 0, missing the estimate of USD 4.3 K.

HeartSciences Inc. Financial Performance (Fiscal 2026)

HeartSciences Inc. reported no meaningful revenue for Fiscal 2026, which ended April 30, 2026. As of April 30, 2026, the company held approximately $1.7 million in cash and cash equivalents and $0.2 million in shareholders’ equity. In connection with the proposed business combination with Fortitude Mining Holdings, the unaudited pro forma combined total shareholders’ equity is projected to be $70.0 million.

Operational Metrics (Fiscal 2026)

During Fiscal 2026, HeartSciences Inc. achieved the full commercial launch of its MyoVista Insights platform. The company also submitted its MyoVista wavECG device to the FDA for 510(k) clearance in December 2025, which remains under review. Fortitude Mining Holdings mined 72,696 ZEC in the six months ended June 30, 2026, representing approximately 28% of overall ZEC production, and possesses an owned power portfolio exceeding 60MW.

Outlook and Guidance

Fortitude Mining Holdings anticipates lowering its Zcash direct cash mining cost from approximately $70 per coin toward approximately $40 per coin, assuming successful equipment deployment and stable market conditions. At Zcash prices exceeding $500, Fortitude estimates its run-rate Adjusted EBITDA could be over $50 million once new machines are delivered and hashing. HeartSciences Inc.’s future strategy for its MyoVista Insights platform includes adding AI-ECG algorithms from leading companies and converting customer discussions into commercial contracts.